'Potential Game Changer' for Psoriasis Gets Green Light From FDA
(MedPage Today) -- The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children 12 or older with moderate...
Source
MedPage Today
Opens original article in a new tab